GLP-1 drugs, such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound, have become some of the most sought-after medicines for weight-loss and diabetes treatment globally. (EPA Images pic)BENGALURU: The combined China-India-Brazil market for weight-loss drugs could grow to US$22 billion by 2035 from US$6.6 billion currently, J.P. Morgan estimated, as improving affordability and broader access drive adoption in largely untapped patient populations.
The addressable market could grow at an annual rate of 15% through 2035, J.P. Morgan analysts led by Yang Huang said in a note on Friday, given the countries' large diabetes and obesity burdens.
GLP-1 drugs, such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound, have become some of the most sought-after medicines for weight-loss and diabetes treatment globally.
